DIAG723 for Hereditary Hemorrhagic Telangiectasia
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
Recruiting
Phase 1
Phase 2
Interventional Study
Hereditary Hemorrhagic Telangiectasia
Pulmonary Arterial Hypertension
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 93 (estimated)
- Sponsor
- Diagonal Therapeutics, Inc. · Industry
Who this trial is looking for
This trial is looking for adults with hereditary hemorrhagic telangiectasia (HHT) to participate in testing a new treatment called DIAG723. Participants will receive either the treatment or a placebo and will be monitored for safety and effectiveness over several weeks.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with hereditary hemorrhagic telangiectasia.
- I have normal liver and kidney function.
- I have a history of nosebleeds and anemia or need for transfusions.
- I have hereditary hemorrhagic telangiectasia with high blood pressure in my lungs.
You may not be able to join if
- I have an active or recent infection.
- I have had a blood clot in the past few months.
- I have taken anti-angiogenic drugs in the last 6 weeks.
- I am pregnant or breastfeeding.
- I have participated in another clinical trial recently.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT).
The study consists of three parts:
Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated i…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients ≥18 years with a clinical or genetic diagnosis of HHT
* Adequate hepatic and renal function
* Part B: Epistaxis and anemia or transfusion/iron history
* Part C: HHT with documented pre-capillary pulmonary arterial hypertension
Exclusion Criteria:
* Active or r…
Contacts